• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大血管受累可预测巨细胞动脉炎的多次复发。

Large-vessel involvement is predictive of multiple relapses in giant cell arteritis.

作者信息

de Mornac Donatienne, Espitia Olivier, Néel Antoine, Connault Jérôme, Masseau Agathe, Espitia-Thibault Alexandra, Artifoni Mathieu, Achille Aurélie, Wahbi Anaïs, Lacou Mathieu, Durant Cécile, Pottier Pierre, Perrin François, Graveleau Julie, Hamidou Mohamed, Hardouin Jean-Benoit, Agard Christian

机构信息

Department of Internal Medicine, Nantes University Hospital, Nantes, France.

Department of Internal Medicine, CHU Nantes, 1 Place Alexis Ricordeau, Nantes, 44093, France.

出版信息

Ther Adv Musculoskelet Dis. 2021 May 18;13:1759720X211009029. doi: 10.1177/1759720X211009029. eCollection 2021.

DOI:10.1177/1759720X211009029
PMID:34046092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8135215/
Abstract

BACKGROUND

Giant cell arteritis (GCA) is the most common systemic vasculitis. Relapses are frequent. The aim of this study was to identify relapse risk factors in patients with GCA with complete large-vessel imaging at diagnosis.

METHODS

Patients with GCA followed in our institution between April 1998 and April 2018 were included retrospectively. We included only patients who had undergone large vascular imaging investigations at diagnosis by computed tomography (CT)-scan and/or positron emission tomography (PET)-scan and/or angio-magnetic resonance imaging (MRI). Clinical, biological, and radiological data were collected. Relapse was defined as the reappearance of GCA symptoms, with concomitant increase in inflammatory markers, requiring treatment adjustment. Relapsing patients (R) and non-relapsing patients (NR) were compared. Relapse and multiple relapses (>2) risk factors were identified in multivariable Cox analyses.

RESULTS

This study included 254 patients (73.2% women), with a median age of 72 years at diagnosis and a median follow up of 32.5 months. At diagnosis, 160 patients (63%) had an inflammatory large-vessel involvement on imaging, 46.1% (117 patients) relapsed at least once, and 21.3% (54 patients) had multiple relapses. The median delay of first relapse after diagnosis was 9 months. The second relapse delay was 21.5 months. NR patients had more stroke at diagnosis than R ( = 0.03) and the brachiocephalic trunk was involved more frequently on CT-scan ( = 0.046), as carotids ( = 0.02) in R patients. Multivariate Cox model identified male gender [hazard ratio (HR): 0.51, confidence interval (CI) (0.27-0.96),  = 0.04] as a relapse protective factor, and peripheral musculoskeletal manifestations [HR: 1.74 (1.03-2.94),  = 0.004] as a relapse risk factor. Peripheral musculoskeletal manifestations [HR: 2.78 (1.23-6.28),  = 0.014], negative temporal artery biopsy [HR: 2.29 (1.18-4.45),  = 0.015], large-vessel involvement like upper limb ischemia [HR: 8.84 (2.48-31.56),  = 0.001] and inflammation of arm arteries on CT-scan [HR: 2.39 (1.02-5.58),  = 0.04] at diagnosis were risk factors of multiple relapses.

CONCLUSION

Male gender was a protective factor for GCA relapse and peripheral musculoskeletal manifestations appeared as a relapsing risk factor. Moreover, this study identified a particular clinical phenotype of multi-relapsing patients with GCA, characterized by peripheral musculoskeletal manifestations, negative temporal artery biopsy, and large-vessel involvement with upper limb ischemia or inflammation of arm arteries.

PLAIN LANGUAGE SUMMARY

46.1% of patients with GCA relapse, and 21.3% undergo multiple relapses;Male gender appears as a protective factor for relapsing in GCA;Peripheral musculoskeletal manifestations are a relapse and multiple relapses risk factor;A negative temporal artery biopsy is predictive of multiple relapses;Large-vessel involvement is predictive of multiple relapses.

摘要

背景

巨细胞动脉炎(GCA)是最常见的系统性血管炎,复发频繁。本研究旨在确定诊断时进行了完整大血管成像的GCA患者的复发危险因素。

方法

回顾性纳入1998年4月至2018年4月在我们机构随访的GCA患者。我们仅纳入了在诊断时通过计算机断层扫描(CT)、正电子发射断层扫描(PET)和/或血管磁共振成像(MRI)进行了大血管成像检查的患者。收集临床、生物学和放射学数据。复发定义为GCA症状再次出现,同时炎症标志物增加,需要调整治疗。比较复发患者(R)和未复发患者(NR)。在多变量Cox分析中确定复发和多次复发(>2次)的危险因素。

结果

本研究纳入254例患者(73.2%为女性),诊断时中位年龄72岁,中位随访32.5个月。诊断时,160例患者(63%)影像学显示有炎症性大血管受累,46.1%(117例患者)至少复发一次,21.3%(54例患者)多次复发。诊断后首次复发的中位延迟时间为9个月。第二次复发延迟时间为21.5个月。NR患者诊断时中风发生率高于R患者(P = 0.03),R患者CT扫描显示头臂干受累更频繁(P = 0.046),颈动脉受累情况类似(P = 0.02)。多变量Cox模型确定男性性别[风险比(HR):0.51,置信区间(CI)(0.27 - 0.96),P = 0.04]为复发保护因素,外周肌肉骨骼表现[HR:1.74(1.03 - 2.94),P = 0.004]为复发危险因素。外周肌肉骨骼表现[HR:2.78(1.23 - 6.28),P = 0.014]、颞动脉活检阴性[HR:2.29(1.18 - 4.45),P = 0.015]、诊断时如上肢缺血等大血管受累[HR:8.8(2.48 - 31.56),P = 0.001]以及CT扫描显示臂动脉炎症[HR:2.39(1.02 - 5.58),P = 0.04]是多次复发的危险因素。

结论

男性性别是GCA复发的保护因素,外周肌肉骨骼表现是复发危险因素。此外,本研究确定了GCA多次复发患者的一种特殊临床表型,其特征为外周肌肉骨骼表现、颞动脉活检阴性以及伴有上肢缺血或臂动脉炎症的大血管受累。

通俗易懂的总结

46.1%的GCA患者复发,21.3%多次复发;男性性别是GCA复发的保护因素;外周肌肉骨骼表现是复发和多次复发的危险因素;颞动脉活检阴性可预测多次复发;大血管受累可预测多次复发。

相似文献

1
Large-vessel involvement is predictive of multiple relapses in giant cell arteritis.大血管受累可预测巨细胞动脉炎的多次复发。
Ther Adv Musculoskelet Dis. 2021 May 18;13:1759720X211009029. doi: 10.1177/1759720X211009029. eCollection 2021.
2
Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis.巨细胞动脉炎有症状血管事件的危险因素:一项对254例诊断时进行大血管成像患者的研究。
Ther Adv Musculoskelet Dis. 2021 Jun 27;13:1759720X211006967. doi: 10.1177/1759720X211006967. eCollection 2021.
3
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study.意大利北部大血管巨细胞动脉炎的复发和长期缓解:一项长期随访研究中的特征和预测因素。
Semin Arthritis Rheum. 2020 Aug;50(4):549-558. doi: 10.1016/j.semarthrit.2020.04.004. Epub 2020 May 20.
4
Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis.正电子发射断层扫描在评估巨细胞动脉炎患者疾病负担和复发风险中的作用。
Clin Rheumatol. 2020 Apr;39(4):1277-1281. doi: 10.1007/s10067-019-04808-7. Epub 2019 Nov 12.
5
Limb arteries involvement assessed by FDG/PET CT at diagnosis of giant cell arteritis and risk of relapse: An observational study.巨细胞动脉炎诊断时 FDG/PET CT 评估的肢体动脉受累与复发风险:一项观察性研究。
Joint Bone Spine. 2024 Sep;91(5):105734. doi: 10.1016/j.jbspin.2024.105734. Epub 2024 Apr 15.
6
Diagnostic performance of F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy.18F-FDG PET-CT 对疑诊巨细胞动脉炎且颞动脉活检阴性患者大血管受累评估的诊断性能。
Ann Nucl Med. 2019 Jul;33(7):512-520. doi: 10.1007/s12149-019-01358-5. Epub 2019 Apr 11.
7
Imaging to predict early relapses after treatment discontinuation in patients with large vessel giant cell arteritis - A cohort study.大血管巨细胞动脉炎患者治疗停止后早期复发的影像学预测 - 一项队列研究。
Semin Arthritis Rheum. 2024 Jun;66:152425. doi: 10.1016/j.semarthrit.2024.152425. Epub 2024 Feb 28.
8
HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study.巨细胞动脉炎中的 HLA-B52 等位基因可能预示着弥漫性大血管血管炎的形成:一项回顾性研究。
Arthritis Res Ther. 2021 Sep 13;23(1):238. doi: 10.1186/s13075-021-02618-4.
9
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases.意大利人群中的 Takayasu 动脉炎和大动脉巨细胞动脉炎。来自单个机构队列的 184 例综合分析。
Semin Arthritis Rheum. 2023 Apr;59:152173. doi: 10.1016/j.semarthrit.2023.152173. Epub 2023 Feb 8.
10
Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity.局限于肢体动脉的巨细胞动脉炎:一种被忽视的临床实体。
Autoimmun Rev. 2015 Apr;14(4):352-7. doi: 10.1016/j.autrev.2014.12.005. Epub 2014 Dec 17.

引用本文的文献

1
Comparative analysis of arterial involvement in predominant cranial and isolated extracranial phenotypes of giant cell arteritis using F-FDG PET-CT.使用F-FDG PET-CT对巨细胞动脉炎主要累及颅脑和孤立性颅外表型时的动脉受累情况进行对比分析。
Arthritis Res Ther. 2024 Dec 28;26(1):230. doi: 10.1186/s13075-024-03464-w.
2
F-FDG-PET/MR imaging to monitor disease activity in large vessel vasculitis.F-FDG-PET/MR 成像用于监测大血管血管炎的疾病活动。
Nat Commun. 2024 Aug 25;15(1):7314. doi: 10.1038/s41467-024-51613-1.
3
Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study.血管超声作为巨细胞动脉炎患者的随访工具:一项前瞻性观察队列研究。
Front Med (Lausanne). 2024 Jul 29;11:1436707. doi: 10.3389/fmed.2024.1436707. eCollection 2024.
4
The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica.丹麦血管炎队列研究:一项全国多中心前瞻性研究的方案,纳入新发和现患的巨细胞动脉炎和风湿性多肌痛患者。
Front Med (Lausanne). 2024 Jul 3;11:1415076. doi: 10.3389/fmed.2024.1415076. eCollection 2024.
5
Evaluation of baseline F-18 FDG positron emission tomography in the diagnosis and assessment of giant cell arteritis.评估 F-18 FDG 正电子发射断层扫描在巨细胞动脉炎诊断和评估中的作用。
Turk J Med Sci. 2024 Jan 5;54(1):69-75. doi: 10.55730/1300-0144.5767. eCollection 2024.
6
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.《Meteoritics 试验:托西珠单抗和糖皮质激素诱导缓解后甲氨蝶呤治疗巨细胞动脉炎的疗效:一项随机、双盲、安慰剂对照、平行分组 II 期研究方案》
Trials. 2024 Jan 15;25(1):56. doi: 10.1186/s13063-024-07905-4.
7
Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?巨细胞动脉炎相关卒中:机制的范围综述及治疗策略的重新思考?
Front Neurol. 2023 Dec 7;14:1305093. doi: 10.3389/fneur.2023.1305093. eCollection 2023.
8
Vasculitis distribution and clinical characteristics in giant cell arteritis: a retrospective study using the new 2022 ACR/EULAR classification criteria.巨细胞动脉炎的血管炎分布及临床特征:一项采用2022年美国风湿病学会/欧洲抗风湿病联盟新分类标准的回顾性研究
Front Med (Lausanne). 2023 Nov 13;10:1286601. doi: 10.3389/fmed.2023.1286601. eCollection 2023.
9
Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study.巨细胞动脉炎患者的快速糖皮质激素递减方案:一项单中心队列研究。
RMD Open. 2023 Jul;9(3). doi: 10.1136/rmdopen-2023-003301.
10
Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force.评估巨细胞动脉炎的治疗结局和疾病活动变化:一项系统文献回顾,代表巨细胞动脉炎 EULAR-ACR 反应标准工作组为 EULAR-ACR 反应标准的制定提供信息。
RMD Open. 2023 Jun;9(2). doi: 10.1136/rmdopen-2023-003233.

本文引用的文献

1
Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event.巨细胞动脉炎诊断时的症状性主动脉炎:主动脉事件的一个预后因素。
Arthritis Res Ther. 2021 Jan 7;23(1):14. doi: 10.1186/s13075-020-02396-5.
2
Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.巨细胞动脉炎患者治疗结局不良的相关因素:大血管病变的临床意义。
Arthritis Res Ther. 2020 Apr 7;22(1):72. doi: 10.1186/s13075-020-02171-6.
3
Giant cell arteritis-related aortitis with positive or negative temporal artery biopsy: a French multicentre study.巨细胞动脉炎相关大动脉炎伴或不伴颞动脉活检阳性:一项法国多中心研究。
Scand J Rheumatol. 2019 Nov;48(6):474-481. doi: 10.1080/03009742.2019.1661011.
4
Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years.50 至 60 岁之间诊断的大血管血管炎:基于 183 例年龄超过 60 岁的病例和 183 例对照的病例对照研究。
Autoimmun Rev. 2019 Jul;18(7):714-720. doi: 10.1016/j.autrev.2019.05.008. Epub 2019 May 4.
5
Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.接受糖皮质激素治疗的患者巨细胞动脉炎复发率:一项荟萃分析。
Arthritis Care Res (Hoboken). 2020 Jun;72(6):838-849. doi: 10.1002/acr.23901. Epub 2020 May 19.
6
Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis.巨细胞动脉炎复发和对糖皮质激素依赖的相关因素。
J Rheumatol. 2020 Jan;47(1):108-116. doi: 10.3899/jrheum.181127. Epub 2019 Mar 15.
7
Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses.在接受托珠单抗治疗的大血管血管炎患者中进行连续白细胞介素-6测量可检测感染情况,并可能预测早期复发。
Ann Rheum Dis. 2019 Jul;78(7):1012-1014. doi: 10.1136/annrheumdis-2018-214704. Epub 2019 Jan 22.
8
Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study.活检证实的巨细胞动脉炎的生存预测因素:一项意大利北部基于人群的研究。
Rheumatology (Oxford). 2019 Apr 1;58(4):609-616. doi: 10.1093/rheumatology/key325.
9
Predictors of positive F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica.预测持续性巨细胞动脉炎患者大血管血管炎 F-FDG PET/CT 扫描阳性的因素。
Semin Arthritis Rheum. 2019 Feb;48(4):720-727. doi: 10.1016/j.semarthrit.2018.05.007. Epub 2018 May 18.
10
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice.EULAR 临床实践中应用影像学检查大血管血管炎的推荐建议。
Ann Rheum Dis. 2018 May;77(5):636-643. doi: 10.1136/annrheumdis-2017-212649. Epub 2018 Jan 22.